- Home
- GH vs JHG Comparison
GH vs JHG Comparison
Compare GH & JHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- JHG
- Stock Information
- Founded
- GH 2011
- JHG 1934
- Country
- GH United States
- JHG United Kingdom
- Employees
- GH N/A
- JHG N/A
- Industry
- GH Medical Specialities
- JHG Investment Managers
- Sector
- GH Health Care
- JHG Finance
- Exchange
- GH Nasdaq
- JHG Nasdaq
- Market Cap
- GH 4.9B
- JHG 5.7B
- IPO Year
- GH 2018
- JHG N/A
- Fundamental
- Price
- GH $49.14
- JHG $36.64
- Analyst Decision
- GH Strong Buy
- JHG Buy
- Analyst Count
- GH 20
- JHG 11
- Target Price
- GH $54.35
- JHG $41.27
- AVG Volume (30 Days)
- GH 2.2M
- JHG 1.2M
- Earning Date
- GH 08-06-2025
- JHG 07-31-2025
- Dividend Yield
- GH N/A
- JHG 4.36%
- EPS Growth
- GH N/A
- JHG N/A
- EPS
- GH N/A
- JHG 2.52
- Revenue
- GH $773,996,000.00
- JHG $2,542,900,000.00
- Revenue This Year
- GH $23.14
- JHG $3.15
- Revenue Next Year
- GH $21.42
- JHG $5.84
- P/E Ratio
- GH N/A
- JHG $14.56
- Revenue Growth
- GH 28.20
- JHG 17.85
- 52 Week Low
- GH $20.14
- JHG $28.26
- 52 Week High
- GH $52.92
- JHG $46.68
- Technical
- Relative Strength Index (RSI)
- GH 62.17
- JHG 53.33
- Support Level
- GH $48.00
- JHG $36.17
- Resistance Level
- GH $51.71
- JHG $37.09
- Average True Range (ATR)
- GH 2.67
- JHG 0.63
- MACD
- GH 0.39
- JHG -0.07
- Stochastic Oscillator
- GH 78.60
- JHG 72.22
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About JHG Janus Henderson Group plc
Janus Henderson Group provides investment management services to retail intermediary (55% of managed assets), self-directed (22%) and institutional (23%) clients. At the end of March 2025, active equities (58%), fixed-income (24%), multiasset (14%) and alternative (4%) investment platforms constituted the company's $373 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (62%), with customers from Europe, the Middle East, Africa, and Latin America (28%) and the Asia-Pacific region (10%) accounting for the remainder.